1-4 of 4
Dirk Erdmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

Saskia M. Brachmann, Andreas Weiss, Daniel A. Guthy, Kim Beyer, Johannes Voshol, Michel Maira, Anirudh Prahallad, Diana Graus Porta, Christian Schnell, Nils Ostermann, Andrea Vaupel, Marc Gerspacher, Catherine Leblanc, Dirk Erdmann, Dario Sterker, Grainne Kerr, Giovannoni Jerome, Victoria Head, Rowan Stringer, Ruben De Kanter, Kearns Jeff, Danielle Roman, Toni Widmer, Peter Wessels, Eloisa Jimenez Nunez, Richard Sedrani, Frederic Zecri, Francesco Hofmann, Jeff Engleman, Edwige Lorthiois, Simona Cotesta
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P124.
https://doi.org/10.1158/1535-7163.TARG-21-P124
Published: 01 December 2021
View article titled, Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models
Journal Articles

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine Fritsch, Alan Huang, Christian Chatenay-Rivauday, Christian Schnell, Anupama Reddy, Manway Liu, Audrey Kauffmann, Daniel Guthy, Dirk Erdmann, Alain De Pover, Pascal Furet, Hui Gao, Stephane Ferretti, Youzhen Wang, Joerg Trappe, Saskia M. Brachmann, Sauveur-Michel Maira, Christopher Wilson, Markus Boehm, Carlos Garcia-Echeverria, Patrick Chene, Marion Wiesmann, Robert Cozens, Joseph Lehar, Robert Schlegel, Giorgio Caravatti, Francesco Hofmann, William R. Sellers
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (5): 1117–1129.
https://doi.org/10.1158/1535-7163.MCT-13-0865
Published: 05 May 2014
View article titled, Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
Open the PDF for Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

Fabienne Baffert, Catherine H. Régnier, Alain De Pover, Carole Pissot-Soldermann, Gisele A. Tavares, Francesca Blasco, Josef Brueggen, Patrick Chène, Peter Drueckes, Dirk Erdmann, Pascal Furet, Marc Gerspacher, Marc Lang, David Ledieu, Lynda Nolan, Stephan Ruetz, Joerg Trappe, Eric Vangrevelinghe, Markus Wartmann, Lorenza Wyder, Francesco Hofmann, Thomas Radimerski
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (7): 1945–1955.
https://doi.org/10.1158/1535-7163.MCT-10-0053
Published: 07 July 2010
View article titled, Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
Open the PDF for Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 in another window
Includes: Supplementary data
Journal Articles

Modulation of drug resistance by artificial transcription factors

Pilar Blancafort, Mario P. Tschan, Sharon Bergquist, Daniel Guthy, Arndt Brachat, Dennis A. Sheeter, Bruce E. Torbett, Dirk Erdmann, Carlos F. Barbas, III
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 688–697.
https://doi.org/10.1158/1535-7163.MCT-07-0381
Published: 17 March 2008
View article titled, Modulation of drug resistance by artificial transcription factors
Open the PDF for Modulation of drug resistance by artificial transcription factors in another window
Includes: Supplementary data